首页>
外国专利>
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COVID-19 AND RELATED PATHOLOGIES
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COVID-19 AND RELATED PATHOLOGIES
展开▼
机译:用于治疗Covid-19和相关病理的药物组合物
展开▼
页面导航
摘要
著录项
相似文献
摘要
The invention relates to a method and to a medicament for use in the treatment of COVID-19 and related pathologies, the medicament comprising or interacting with one or more conserved regions of at least 4 consecutive amino acids with a 100% match present in both the SARS-CoV-2 proteome and the human proteome, wherein the one or more conserved regions are preferably selected by: a. identification of one or more conserved regions of at least 4 consecutive amino acids with a 100% match between the SARS-CoV-2 proteome and the human proteome; b.identification of at least one pathway class from a systematic database comprising a plurality of human physiological pathway classes, each class comprising a plurality of human proteins that are functionally related to the said physiological pathway, wherein the said at least one pathway class shares at least one pathology and/or complication of the COVID-19 infection as a result of dysfunction in the said pathway and comprises at least one human protein comprising one or more conserved regions of at least 4 consecutive amino acids that have a 100% match with the SARS-CoV-2 proteome; and c. selecting the said identified one or more conserved regions for the preparation of the medicament. Based on this approach peptides were selected for the treatment of COVID-19 and several pathologies and complications that can occur in the context of COVID-19, but also as a separate disease, pathology, or complication. The invention also relates to a vaccine comprising one or more agents interacting with at least one region of at least 4 consecutive amino acids present in the SARS-CoV-2 proteome, not conserved between the SARS-CoV-2 proteome and the human proteome. Finally, the invention can provide a molecular and cellular explanation for the deviant infectivity, clinical behaviour, and pathology of emerging SARS-CoV-2 variants over time, to design vaccines to specifically prevent these complications, and to select peptides as therapeutic modality to treat these clinical manifestations and complications.
展开▼